Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aspirin + minocycline is a combination of two small molecule drugs—aspirin, an anti-inflammatory and antiplatelet agent, and minocycline, a tetracycline-class antibiotic with additional neuroprotective and anti-inflammatory properties. This combination has been investigated in preclinical models for its potential to enhance cerebroprotection by targeting matrix metalloproteinase (MMP-2 and MMP-9) activity in cerebral ischemia. It has also been studied as adjunctive therapy in bipolar depression due to their combined anti-inflammatory effects. Aspirin acts primarily through irreversible inhibition of cyclooxygenase enzymes (COX-1/COX-2), reducing prostaglandin synthesis; minocycline inhibits bacterial protein synthesis by binding the 30S ribosomal subunit but also exhibits neuroprotective actions via inhibition of microglial activation and MMPs[2][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + minocycline.